These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Bioresorbable scaffold - A magic bullet for the treatment of coronary artery disease? Brie D; Penson P; Serban MC; Toth PP; Simonton C; Serruys PW; Banach M Int J Cardiol; 2016 Jul; 215():47-59. PubMed ID: 27111160 [TBL] [Abstract][Full Text] [Related]
8. Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry. Latini RA; Granata F; Ielasi A; Varricchio A; Moscarella E; Tespili M; Cortese B Catheter Cardiovasc Interv; 2016 Sep; 88(3):380-7. PubMed ID: 27038332 [TBL] [Abstract][Full Text] [Related]
9. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. Wiebe J; Nef HM; Hamm CW J Am Coll Cardiol; 2014 Dec; 64(23):2541-51. PubMed ID: 25500240 [TBL] [Abstract][Full Text] [Related]
10. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries. Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648 [TBL] [Abstract][Full Text] [Related]
11. A hybrid strategy with bioresorbable vascular scaffolds and drug eluting stents for treating complex coronary lesions. Jabbour RJ; Ielasi A; Tanaka A; Leoncini M; Cortese B; Grigis G; Mitomo S; Regazzoli D; Di Palma G; Rapetto C; Tespili M; Colombo A; Latib A Cardiovasc Revasc Med; 2017; 18(5S1):S4-S9. PubMed ID: 28314675 [TBL] [Abstract][Full Text] [Related]
12. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532 [TBL] [Abstract][Full Text] [Related]
13. Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction). Brugaletta S; Gori T; Low AF; Tousek P; Pinar E; Gomez-Lara J; Scalone G; Schulz E; Chan MY; Kocka V; Hurtado J; Gomez-Hospital JA; Münzel T; Lee CH; Cequier A; Valdés M; Widimsky P; Serruys PW; Sabaté M JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):189-197. PubMed ID: 25616924 [TBL] [Abstract][Full Text] [Related]
14. Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away? de Pommereau A; de Hemptinne Q; Varenne O; Picard F Arch Cardiovasc Dis; 2018 Apr; 111(4):229-232. PubMed ID: 29678390 [No Abstract] [Full Text] [Related]
15. Procedural resources utilization and clinical outcomes with bioresorbable everolimus-eluting scaffolds and Pt-Cr everolimus-eluting stent with resorbable abluminal polymer in clinical practice. A randomized trial. de la Torre Hernandez JM; Garcia Camarero T; Lee DH; Sainz Laso F; Veiga Fernandez G; Pino T; Rubio S; Legarra P; Valdivia JR; Zueco Gil J Catheter Cardiovasc Interv; 2017 Aug; 90(2):E25-E30. PubMed ID: 27807948 [TBL] [Abstract][Full Text] [Related]
16. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622 [TBL] [Abstract][Full Text] [Related]
17. Fracture with the newer bioresorbable vascular scaffolds. Elwany M; Di Palma G; Cortese B Catheter Cardiovasc Interv; 2017 Oct; 90(4):582-583. PubMed ID: 28295999 [TBL] [Abstract][Full Text] [Related]
18. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial. Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961 [TBL] [Abstract][Full Text] [Related]
19. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry. Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety of bioresorbable scaffolds: insights from a network meta-analysis including 91 trials. Kang SH; Gogas BD; Jeon KH; Park JS; Lee W; Yoon CH; Suh JW; Hwang SS; Youn TJ; Chae IH; Kim HS EuroIntervention; 2018 Mar; 13(16):1904-1913. PubMed ID: 29278353 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]